Objectives: Remission is a widely accepted goal for treatment of rheumatoid arthritis (RA) but has to be sustained to arrest joint damage and disability. However, appropriate criteria for the assessment of sustained remission in long-term studies are not established. Therefore, we have compared the DAS28 remission criterion, the SDAI Cr criteria and the new Booleanbased set of criteria, Boolean Cr, and assessed the association of these criteria with radiographic and functional outcome.
Article summary
Article focus
To assess the prevalence of sustained remission in early RA during the first 8 years after inclusion into the study.
To study the feasibility in long-term studies of the most frequently used remission criteria, the DAS28 remission criterion and the new ACR/EU criteria.
To assess the association of these criteria with radiographic and functional outcome.
Key messages
Sustained remission was infrequent by all criteria used but most frequent by the DAS28 criterion.
Patients in sustained remission by the DAS28 criterion did not have worse function nor more evidence of joint destruction compared with the more stringent criteria.
The DAS28 criterion may be used in long-term studies until more accurate criteria become available.
Strength and limitations of this study + + + + Data are derived from a cohort of patients with early RA followed in a structured way for up to eight years. The principal aim in the treatment of rheumatoid arthritis (RA) is to suppress the inflammatory process (the disease activity) and achieve remission. Remission may be defined as a state with no or little disease activity. However, remission must be sustained in order to eliminate or arrest joint damage. [1] Several sets of criteria for remission have been proposed and applied in a number of studies of RA. The original American Rheumatism Association (ARA) remission criteria are infrequently used today since all components of the criteria are not included in the current core set of variables. [2] A Disease Activity Score (DAS) less than 1.6 was found to correspond well to the ARA remission criteria and was proposed as a remission criterion. [3, 4] Later, the DAS remission criterion was modified by a 28 joint count to the DAS28 remission criterion, DAS28 less than 2.6 (DAS28 Cr), which has been widely used. Since then, more stringent criteria have been developed, e.g. the Simplified Disease Activity Index less than 3.3 remission criterion (SDAI Cr). [5] Recently, the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) in collaboration proposed that remission in RA may be defined either according to the SDAI Cr or to the new Boolean-based set of criteria (Boolean Cr). [6] The Boolean Cr have been shown to perform well in clinical trials but their utility in long-term observational studies remains to be demonstrated. [6] The most frequently used criterion, the DAS28 Cr, has been questioned since patients may be in remission by this criterion in spite of several swollen and tender joints.
On the basis of these considerations, long-term sustained remission by different criteria has been studied in the BARFOT (Better AntiRheumatic PharmacOTherapy) observational study of patients with early RA and related to disability and radiographic joint damage. [7] Patients and methods
Patients
In all, 698 patients with RA were consecutively included in the BARFOT observational study [7] from September 1995 to September 1999 and 527 of these have completed eight years. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   6 171 patients were lost to follow-up, of these 119 had died, 9 had moved, 2 rejected further follow-up visits and in 41 cases the cause is unknown.
The group of patients lost to follow-up were older (mean age 67 vs 54 years, p=0.001), had higher HAQ (mean 1.09 vs 0.97, p=0.043) and were somewhat less frequently positive for antibodies to citrullinated proteins (ACPA) (49% vs 58%, p=0.044).
All patients should fulfill the ACR criteria for classification of RA and should have a disease duration of 12 months or less. The patients were checked by a structured protocol at baseline and after 6 months and 1, 2, 5 and 8 years. A few patients had been treated before inclusion with disease modifying drugs (DMARDs) or glucocorticoids (GCs) but treatment was in most patients initiated at inclusion (baseline). The patients were treated by the rheumatologists´ preferences.
Methods

Clinical assessments
Disease activity was measured by number of swollen and tender joints calculated on 28 joints, patient global assessment of disease activity (PatGA) on a visual analogue scale (VAS) of 10 cm, and the physician´s global assessment of the disease activity (PhGA) measured on a 5 stage Likert scale, which was transformed to a VAS of 10 cm. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 "DAS28-3 Cr", "Boolean-3 Cr" and "SDAI-4 Cr": The only difference from the original criteria is that VAS PatGA has been excluded from the original criteria.
Sustained remission was defined as remission at all four follow-up visits at 1, 2, 5 and 8 years, never remission as absence of remission at all visits, while intermittent remission was defined as remission at one, two or three of these four follow-up visits.
Radiographic assessment
Posterior-anterior radiographs of the hands and feet were obtained at study entry in 630 patients, at 1 year in 594, at 2 years in 613, at 5 years in 560 and at 8 years in 468 patients.Patients not having any radiographs did not differ significantly in baseline characteristics from patients with radiographs (data not shown).
Radiographic joint damage was assessed according to the van der Heijde modification of the Sharp score.
[11] Total scores (SHS) are presented (range 0-448). The films were read by one of two experienced readers. Double readings of a fraction of films showed good agreement between the two readers (data not shown). 
Radiographic progression
Results
Demographic and clinical baseline characteristics
At baseline, the mean age of the patients was 57 years and 64% were women. The mean DAS28 was 5.23, the mean HAQ 1.0 and the median SHS was 1. Forty-two per cent of the patients were started on GC treatment and 87% on non-biologic DMARDs, table 1. The frequencies of remission increased from 6 months and onwards by all criteria used. Table   II shows that the remission rates from one to 8 years were most frequent by the DAS28 based criteria, irrespective of whether PatGA was excluded or not. Remissions by the Boolean Cr and the SDAI Cr were less frequent but the frequencies increased when PatGA was excluded from the criteria. 
Number of patients in remission at one, two, three or all of the 4 follow-up visits
Influence of number of tender and swollen joints on sustained remission
The DAS28 formula allows classification of a patient as in remission even in the presence of several swollen or tender joints. To investigate whether this might be the case also in patients in sustained remission in this study, the number of tender and swollen joints, which were components of DAS28 in these patients, were counted. Table IV shows that more than one or two swollen or tender joint were infrequent. 
Drug treatment
At baseline, one and 2 years, information on GC and DMARD treatment was available in all or almost all patients while no such information was available at 5 years in 11 and13% and at 8 years 27 and 28%, respectively. At baseline there were no statistically significant differences between remission groups in frequency and kind of DMARD treatment. At the follow-up visit at 8 years significantly more patients in the sustained remission groups (48-64%) had stopped DMARDs than was the case in the intermittent (26-35%) and never remission groups (19-23%). The differences were statistically significant, irrespective of criteria used, p<0.002 or less. Only 0-5% of the patients in the sustained remission groups were treated with biologics vs 9-15% and 16-18% of the patients in the intermittent and never remission groups, respectively. Post hoc analyses showed that this was significant when the DAS28-based criteria and the Boolean-3 Cr were used.
At baseline 42% of the patients in all remission groups were started on glucocorticoids (GCs). After 8 years fewer patients in sustained remission were treated with GCs (0-5%) than in the intermittent (16-20%) and the never remission groups (24-28%). The differences were statistically significant, irrespective of criteria used, p <0.03 or less).
Radiographic joint damage in the sustained remission groups
Radiographic joint damage as assessed by SHS increased significantly from year 1 to 8 in all remission groups, least in the sustained remission groups and most in the groups with no remissions at all ( fig. 1 a-f ). In the sustained remission groups, the mean (SD) increase in SHS between baseline and 8 years were similar: 7.4 (8.6) by the DAS28 Cr, 7.3 (9.3) by the Performance of the criteria Table V displays the performance of the criteria. There was a general tendency for sustained remission to be associated with absence of radiographic progression. The association varied somewhat between criteria, the sensitivity was low and the likelihood ratios were small and not statistically significant for the Boolean-based and SDAI-4 criteria. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In this study, long-term sustained remission was considerably less frequent, 3% of the patients by the Boolean Cr, 5% by the SDAI Cr and 14% by the DAS28 Cr. In the study by Shahouri, the probability of having 2 or more visits in remission during 2 years was at most 2.8% for the Boolean Cr and 4.2% for the SDAI. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 who report that 91% of the patients in their study gave the same (77%) or almost the same (14%) rating to the questions "describe your health to-day" and "assess the activity of your disease".
[16] A way to overcome this bias would be to phrase the questions more distinctly.
The low frequency of sustained remission by the Boolean Cr criteria suggests that they may be too stringent to be suitable for long-term studies in clinical practice. In the present study, Gender may influence remission rates.
[16] In the BARFOT study we have earlier reported that sustained remission from year 2 to 5, determined by the DAS28 <2.6 criterion, was significantly less frequent in women than in men.
[27] Furthermore, women had higher DAS28 after five and eight years than men, but no gender difference was observed in radiographic progression. [28, 29] Similarly, in the present study, sustained remission by all criteria was significantly less frequent in women than in men, while radiographic joint damage was similar (data not shown). The explanation to this inconsistency is probably that non inflammatory pain confounds the measurement of disease activity in women.
Ideally The validity of the Boolean Cr and SDAI Cr has been established in short or medium term studies by demonstrating satisfactory likelihood ratios for "good radiographic outcome" of being in remission. [6, 13] In this study, as in another long-term study [18], radiographic progression was common also in patients in sustained remission, regardless of criteria used, and consequently, the likelihood ratios were small. However, the degree of radiographic damage was minor in the groups of patients in sustained remission and often below the "the lowest value of minor radiological change".
[12] Similar results were obtained using different cut-off values for radiographic progression (data not shown). So, sustained remission by all criteria seems to be associated with slow long-term radiographic progression. 
Conclusion
The present study has focused on finding suitable criteria for identifying patients in long-term sustained remission to be used in the assessment of the disease course and outcome of RA.
The data suggest that the Boolean Cr, although performing well in clinical trials, are very stringent and bring about risks for misclassifications mainly due to the requirement of a very low PatGA, and hence risk for over treatment. Similar objections may be made to the use of the SDAI Cr, which may make these criteria less appropriate for use in long-term studies in which PatGA frequently may be increased due to co-morbidities. Both these sets of criteria classified more patients in sustained remission when PatGA was excluded. However, using criteria without PatGA means that the much wanted patient perspective of the criteria is abandoned.
[34] Furthermore, cut-offs for remissions have not been established for criteria without VAS PatGA. The DAS28 Cr performed reasonably well in this eight year study and presented very little of previously observed drawbacks. In spite of more patients in sustained remission by DAS28 Cr, radiographic damage and disability was apparently not worse than what was seen with the other criteria and the patients´ perspective was preserved. The DAS28
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